PT792275E - Promedicamento antiviral melhorado - Google Patents

Promedicamento antiviral melhorado

Info

Publication number
PT792275E
PT792275E PT95940014T PT95940014T PT792275E PT 792275 E PT792275 E PT 792275E PT 95940014 T PT95940014 T PT 95940014T PT 95940014 T PT95940014 T PT 95940014T PT 792275 E PT792275 E PT 792275E
Authority
PT
Portugal
Prior art keywords
average
improved antiviral
antiviral
improved
phosphonoacids
Prior art date
Application number
PT95940014T
Other languages
English (en)
Inventor
Karl Y Hostetler
Ganesh D Kini
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of PT792275E publication Critical patent/PT792275E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
    • C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT95940014T 1994-11-15 1995-11-15 Promedicamento antiviral melhorado PT792275E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/340,161 US5696277A (en) 1994-11-15 1994-11-15 Antiviral prodrugs

Publications (1)

Publication Number Publication Date
PT792275E true PT792275E (pt) 2004-09-30

Family

ID=23332146

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95940014T PT792275E (pt) 1994-11-15 1995-11-15 Promedicamento antiviral melhorado

Country Status (11)

Country Link
US (2) US5696277A (pt)
EP (1) EP0792275B1 (pt)
JP (1) JPH10508858A (pt)
AT (1) ATE260926T1 (pt)
AU (1) AU700651B2 (pt)
CA (1) CA2205136C (pt)
DE (1) DE69532642T2 (pt)
DK (1) DK0792275T3 (pt)
ES (1) ES2217287T3 (pt)
PT (1) PT792275E (pt)
WO (1) WO1996015132A1 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
SE9603726D0 (sv) * 1996-10-11 1996-10-11 Astra Ab Novel compounds
SE9604582D0 (sv) * 1996-12-13 1996-12-13 Astra Ab Novel compounds
US6686462B2 (en) 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
EA008609B1 (ru) 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
US6444837B1 (en) * 1998-07-13 2002-09-03 University Of Southern California Synthesis and antiviral activity of a series of pyrophosphate analogs
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ES2579903T3 (es) 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
ATE408410T1 (de) 1998-11-02 2008-10-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
WO2001047511A2 (en) * 1999-12-29 2001-07-05 The Regents Of The University Of California Treatment of drug-resistant human immunodeficiency virus infection
DK1284720T3 (da) 2000-03-29 2007-01-15 Univ Georgetown L-FMAU til behandling af hepatitis delta-virusinfektion
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
US20030114385A1 (en) * 2001-04-27 2003-06-19 Cathers Brian E. Viral enzyme activated prototoxophores and use of same to treat viral infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
EP1536804A4 (en) 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
EP2799442A1 (en) 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
ES2547002T3 (es) 2002-09-13 2015-09-30 Novartis Ag Beta-L-2' desoxinucleósidos para el tratamiento de cepas de VHB resistentes
US20070207973A1 (en) * 2002-09-24 2007-09-06 Koronis Pharmaceuticals, Incorporated 1,3,5-Triazines for Treatment of Viral Diseases
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
RU2005123395A (ru) * 2002-12-23 2006-01-27 Айденикс (Кайман) Лимитед (Ky) Способ получения 3-нуклеозидных пролекарств
ES2586668T3 (es) 2003-05-30 2016-10-18 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
AU2004258750A1 (en) 2003-07-25 2005-02-03 Centre National De La Recherche Scientifique -Cnrs Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
US20070211471A1 (en) * 2003-10-27 2007-09-13 Wimberly Randal L Dual Reflector System
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
SI2574341T1 (sl) 2004-03-29 2017-08-31 University Of South Florida Učinkovito zdravljenje tumorjev in raka s triciribin fosfatom
US20060040944A1 (en) * 2004-06-23 2006-02-23 Gilles Gosselin 5-Aza-7-deazapurine derivatives for treating Flaviviridae
MX2007003085A (es) 2004-09-14 2007-08-02 Pharmasset Inc Preparacion de 2'-fluoro-2'-alquilo sustituido u otras ribofuranosil pirimidinas y purinas opcionalmente sustituidas y sus derivados.
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP2842559A3 (en) 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
AU2006294807B2 (en) 2005-09-26 2013-01-17 Gilead Pharmasset Llc Modified 4'-nucleosides as antiviral agents
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
US7950880B2 (en) * 2006-10-18 2011-05-31 Kennametal Inc. Spiral flute tap
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2254582B1 (en) 2008-01-25 2016-01-20 Chimerix, Inc. Methods of treating viral infections
CA2722308C (en) 2008-04-15 2024-02-27 Rfs Pharma, Llc. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
MX2011006891A (es) 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
BR112015023705A8 (pt) 2013-03-15 2020-03-17 Univ California compostos, composições farmacêuticas, usos de um composto, e método para síntese do composto da fórmula (ia)
NZ716840A (en) 2013-08-27 2017-06-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
PL3194411T3 (pl) 2014-09-15 2022-06-20 The Regents Of The University Of California Analogi nukleotydów
WO2017048956A1 (en) 2015-09-15 2017-03-23 The Regents Of The University Of California Nucleotide analogs
US11033600B2 (en) 2016-07-28 2021-06-15 Kansas State University Research Foundation Protease transition state inhibitor prodrugs
CA3105038A1 (en) * 2018-06-26 2020-01-02 Tsrl, Inc. Metabolically stable prodrugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7607496L (sv) * 1976-07-01 1978-01-02 Astra Laekemedel Ab Sett for bekempning av virusinfektioner
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
US5072032A (en) * 1989-06-21 1991-12-10 Mckenna Charles E Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
EP0673256A4 (en) * 1992-12-09 1997-01-29 Indiana University Foundation SUPPRESSION OF MYELOID CELLS.
US5696277A (en) * 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs

Also Published As

Publication number Publication date
EP0792275B1 (en) 2004-03-03
US6002029A (en) 1999-12-14
ES2217287T3 (es) 2004-11-01
AU700651B2 (en) 1999-01-14
JPH10508858A (ja) 1998-09-02
CA2205136C (en) 2008-01-22
CA2205136A1 (en) 1996-05-23
DK0792275T3 (da) 2004-07-05
AU4163596A (en) 1996-06-06
DE69532642D1 (de) 2004-04-08
EP0792275A4 (en) 1998-02-25
DE69532642T2 (de) 2005-06-30
EP0792275A1 (en) 1997-09-03
US5696277A (en) 1997-12-09
WO1996015132A1 (en) 1996-05-23
ATE260926T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
PT792275E (pt) Promedicamento antiviral melhorado
DE69426904D1 (de) Phosphonat-Nukleotid Ester-Derivate
DE69132822D1 (de) System zur Synchronisierung von Halbbildern, bei dem der Zeilensprung erhalten bleibt
AU2156092A (en) Use of polymerized hemoglobin to increase the antitumor effect of the ionizing radiation
MX9202839A (es) 4-aminoquinolinas y composiciones farmaceuticas de las mismas.
MX9205981A (es) Administracion transdermica de melatonina.
DE69305413D1 (de) Pulverisierungsvorrichtung
DE69204228T2 (de) Paar von vorderen und hinteren Reifen.
KR930702893A (ko) 상보시스템을 저해하거나 또는 면역활성을 억제하는 성분물
DE69328050T2 (de) Rücklaufsperre
DE69121446T2 (de) Zerstäubungssystem
FI964619A (fi) Epilepsialääkkeiden iholle annostelu
NO840104L (no) Oksalkylerte polyamidoaminer, samt anvendelse av dem
DE69311862T2 (de) Kontinuierliche Dispergiervorrichtung
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
ITMI912652A0 (it) Medicamento ad attivita' antielasica
ES1021090Y (es) Gaveta con dos costados de gaveta.
ES1022839Y (es) Bragas monouso.
KR940006900U (ko) 유아용 멜빵
KR970000135U (ko) 아기용 멜빵
KR960031081U (ko) 안전거리 지시형 백밀러
KR950010435U (ko) 모니터의 프론트마스크 구조
SE9203298D0 (sv) Laekemedel med antidopamineffekt
IT8348050A0 (it) Sostanze ss 12538 fisiologicamente attive, loro preparazione e microorganismo che le produce
ES1024577Y (es) Juego ciclista de mesa.